BNTX BioNTech SE
USHealthcareAs of 2026-07-10 16:00
Why BNTX matters now
BioNTech SE (BNTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $91.49 with -1.60% on the session and $23.14B in market capitalization; recent performance reads 1-month +3.53% and YTD -4.53%.
The latest financial table shown here is Q1 2026, with revenue of $120.0M, net income of $-540.6M, and EPS of $-2.14. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 3.4%.
The latest indexable market news headline is "2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $135.00; recent insider activity includes Hanekamp Annemarie filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.08
P/S
7.18
EV/EBITDA
-14.89
DCF Value
$48.69
FCF Yield
3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.6%
Operating Margin
-52.1%
Net Margin
-44.7%
ROE
-6.7%
ROA
-5.9%
ROIC
-7.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $120.0M | $-540.6M | $-2.14 |
| Q4 2025 | $898.9M | $-302.1M | $-1.23 |
| FY 2025 | $2.76B | $-1.09B | $-4.51 |
| Q3 2025 | $1.52B | $-28.7M | $-0.12 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$132.33
Target (Median)
$135.00
Target Range
$96.00 - $158.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
DE
Exchange
—
Beta
1.32
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.